Fierce Pharma

Of the top 10 biopharma M&A deals of 2025, six [...]

A court in Baltimore has ordered Johnson & Johnson to [...]

A patient in an open label extension study of Pfizer’s [...]

Neurocrine’s Ingrezza, approved to treat certain uncontrolled movements, failed to [...]

Drug pricing, layoffs, personnel moves and other topics drove reader [...]

Pharma giant AstraZeneca extended its supply deal with Michigan-based medical [...]

CMS’ Innovation Center has released two new drug pricing models [...]

Boehringer’s Jascayd can now crack open the rare progressive pulmonary [...]

Slated for a Dec. 26 decision on Cytokinetics’ aficamten, the [...]

Samsung Bio’s U.S. subsidiary will pay $280 million to acquire [...]